Chargement des cours...
Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Actualités Accéder au fil d'actualités
Rein Therapeutics terminates financing pacts with Yorkville without penalties
Rein Therapeutics has terminated its Pre-Paid Advance Agreement and Standby Equity Purchase Agreement with Yorkville; according to an SEC filing, the company will incur no penalties or fees. The company did not sell any common stock under the equity purchase agreement and had previously received up to $3 million in advance payments; a third advance payment of $1 million was also secured. Separately, Rein reported positive data for LTI-03 against idiopathic pulmonary fibrosis, the FDA lifted the clinical hold on the Phase 2 study, and recruitment is expected to start in late 2025/early 2026; Brookline Capital Markets upgraded the stock to "buy." » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | juin 2026 | |
|---|---|---|
| Chiffre d'affaires | 0 | - |
| Bénéfice brut | 0 | - |
| Bénéfice net | 1,25 M | 2 478,31 % |
| EBITDA | -158,67 k | 194,17 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 158,98 M € |
Nombre d'actions | 17,83 M |
Plus haut/bas sur 52 semaines | 10,25 € - 8,71 € |
| Dividendes | Non |
Bêta | 0,01 |
Ratio P/E | 74,48 |
Ratio PEG | -0,04 |
Ratio P/B | 1,04 |
Ratio P/S | 0,00 |
Profil de l'entreprise
| Nom | YORKVILLE ACQUI. A O.N. |
| PDG | Troy J. Rillo |
| Employés | 2 |
Découvrir des actifs
Les actionnaires de YORKVILLE ACQUI. A O.N. investissent également dans les actifs suivants
